A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

Summary

The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.

Timeline

Start

2006-09

Primary completion

2007-11

Completion

2007-11

Outcome

Mixed primary results

registry analysis (unspecified test); Placebo vs Pregabalin 150 mg/Day; p = 0.262; Mean Difference (Final Values) -0.31 (95% CI -0.85 to 0.23); ANCOVA NCT00394901 ↗

registry analysis (unspecified test); Placebo vs Pregabalin 300 mg/Day; p = 0.002; Mean Difference (Final Values) -0.86 (95% CI -1.39 to -0.32); ANCOVA NCT00394901 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pregabalin	Small molecule	150 mg	Oral
Subject	Pregabalin	Small molecule	300 mg	Oral
Subject	Pregabalin	Small molecule	600 mg	Oral

Indications